Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis

11 Jun 2018

Abstract excerpt

Leukemic transformation is the most dreaded complication in patients with myeloproliferative neoplasms (MPN); overall risk is estimated at 14% for primary myelofibrosis (PMF), 7% for polycythemia vera (PV) and 4% for essential thrombocythemia (ET) 1 . The dismal prognosis of blast phase MPN (MPN-BP) was recently underlined in a large Mayo Clinic study of 248 informative patients and further validated in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Kruppel-like factors research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29891917
DOI: 10.1038/s41408-018-0095-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosisPMID 29891917Read ↗

Accelerated and blast phase myeloproliferative neoplasms.Semantic proximity Read ↗

Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic OptionsSemantic proximity Read ↗

Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.Semantic proximity Read ↗

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Prodromal myeloproliferative neoplasms: the 2008 WHO classification.Semantic proximity Read ↗

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.Semantic proximity Read ↗

Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?Semantic proximity Read ↗

Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.Semantic proximity Read ↗

Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasmSemantic proximity Read ↗

Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?Semantic proximity Read ↗

Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.Semantic proximity Read ↗

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.